Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-0003, Japan.
J Hepatobiliary Pancreat Sci. 2018 Feb;25(2):155-161. doi: 10.1002/jhbp.524. Epub 2018 Jan 16.
MicroRNAs (miRNAs) encapsulated in the exosomes of plasma is of interest as stable and minimally invasive biomarkers for recurrence and prognosis in cancer patients. The aim of this study was to clarify the predictive and prognostic value of plasma exosomal microRNA-451a (miR-451a) in patients with pancreatic ductal adenocarcinoma (PDAC).
Microarray-based expression profiling of miRNAs derived from exosomes in the plasma of six PDAC patients with UICC stage II was employed to identify a biomarker to distinguish between patients with and without recurrence. For validation analysis, plasma exosome samples of other 50 PDAC patients were measured by TaqMan MicroRNA assays.
In the miRNA microarray analyses, miR-451a showed the highest upregulation in the stage II patients who showed recurrence after surgery. In the relationship to pathological factors, exosomal miR-451a showed a significant association with tumor size and stage. The overall survival (OS) and disease-free survival rates (DFS) of the high exosomal miR-451a patients were significantly worse than those of the low miR-451a patients. In Cox proportional hazards model analysis, exsomal miR-451a showed significance to OS and DFS.
Plasma exosomal miR-451a levels may be a useful minimally invasive biomarker for the prediction of recurrence and prognosis in PDAC patients.
外泌体中的 microRNAs（miRNAs）作为癌症患者复发和预后的稳定且微创生物标志物引起了关注。本研究旨在阐明血浆外泌体 microRNA-451a（miR-451a）在胰腺导管腺癌（PDAC）患者中的预测和预后价值。
采用 miRNA 芯片技术对 6 例 UICC Ⅱ期 PDAC 患者血浆外泌体来源的 miRNA 进行表达谱分析，以鉴定区分有和无复发患者的生物标志物。为了验证分析，采用 TaqMan miRNA 检测试剂盒测量了其他 50 例 PDAC 患者的血浆外泌体样本。
miRNA 芯片分析显示，在手术后复发的Ⅱ期患者中，miR-451a 表达上调最高。在与病理因素的关系方面，外泌体 miR-451a 与肿瘤大小和分期显著相关。高外泌体 miR-451a 患者的总生存率（OS）和无病生存率（DFS）明显差于低 miR-451a 患者。在 Cox 比例风险模型分析中，外泌体 miR-451a 对 OS 和 DFS 具有显著意义。
血浆外泌体 miR-451a 水平可能是预测 PDAC 患者复发和预后的有用微创生物标志物。
